Published in Medical Letter on the CDC and FDA, February 14th, 2010
Global REVLIMID Net Product Sales Increased 35 Percent to $497 Million
Global VIDAZA Net Product Sales Increased 68 Percent to $117 Million
Global THALOMID® Net Product Sales of $108 Million
Non-GAAP Operating Income Increased 48 Percent to $337 Million; GAAP Operating Income $283 Million
Non-GAAP Net Income Increased to $290 Million; GAAP Net Income $254 Million
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.